Patents by Inventor Vivian Berlin

Vivian Berlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunosuppressant Target Proteins
    Publication number: 20110065898
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
    Type: Application
    Filed: November 25, 2009
    Publication date: March 17, 2011
    Applicant: ARIAD Gene Therapeutics, Inc.
    Inventors: Vivian Berlin, Maria Isabel Chiu, Guillaume Cottarel, Veronique Damagnez
  • Immunosuppressant target proteins
    Publication number: 20050059803
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
    Type: Application
    Filed: June 24, 2004
    Publication date: March 17, 2005
    Applicant: ARIAD Gene Therapeutics, Inc.
    Inventors: Vivian Berlin, Maria Chiu, Guillaume Cottarel, Veronique Damagnez
  • Assays and reagents for identifying anti-fungal agents, and uses related thereto
    Patent number: 6727082
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis. Another aspect of the present invention relates to novel Candida genes and gene products.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: April 27, 2004
    Assignee: GPC Biotech Inc.
    Inventors: Vivian Berlin, Veronique Damagnez, Susan E. Smith
  • Candida geranylgeranyl-protein transferase polypetide, compositions and methods related thereto
    Patent number: 6696280
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis. Another aspect of the present invention relates to novel Candida genes and gene products.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: February 24, 2004
    Assignee: GPC Biotech, Inc.
    Inventors: Vivian Berlin, Veronique Damagnez, Susan E. Smith
  • Immunosuppressant target proteins
    Patent number: 6509152
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: January 21, 2003
    Assignee: Ariad Gene Therapeutics, Inc.
    Inventors: Vivian Berlin, Maria Isabel Chiu, Guillaume Cottarel, Veronique Damagnez
  • Assays and reagents for identifying anti-fungal agents, and uses related thereto
    Publication number: 20020168748
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis.
    Type: Application
    Filed: August 31, 2001
    Publication date: November 14, 2002
    Inventors: Vivian Berlin, Veronique Damagnez, Susan E. Smith
  • Immunosuppressant target proteins
    Patent number: 6464974
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes and provides, e.g., isolated polypeptides, nucleic acids encoding such, antibodies, screening methods, and diagnostic and therepeutic methods.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: October 15, 2002
    Assignee: Ariad Pharmaceuticals
    Inventors: Vivian Berlin, Maria Isabel Chiu, Guillaume Cottarel, Veronique Damagnez
  • Nucleic acids for identifying anti-fungal agents, and uses related thereto
    Patent number: 6455281
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis. Another aspect of the present invention relates to novel Candida genes and gene products.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: September 24, 2002
    Assignee: GPC Biotech Inc.
    Inventors: Vivian Berlin, Veronique Damagnez, Susan E. Smith
  • ASSAYS AND REAGENTS FOR IDENTIFYING ANTI-FUNGAL AGNETS, AMD USES RELATED THERETO
    Publication number: 20020107226
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis.
    Type: Application
    Filed: July 22, 1999
    Publication date: August 8, 2002
    Inventors: VIVIAN BERLIN, DAVID E. LEVIN, YOSHIKAZU OHYA
  • Compositions and methods for inhibiting fungal growth
    Patent number: 6423519
    Abstract: The present invention relates to compositions and methods for inhibiting fungal growth. In particular, the present invention relates to methods for use as anti-fungal agents of inhibitors, and compositions thereof, of fungal GGPTase. The inhibitors of fungal GGPTase may be peptides, peptidomimetics, or non-peptides.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: July 23, 2002
    Assignee: GPC Biotech Inc.
    Inventors: Gustave Bergnes, Vivian Berlin, Jon Come, Arthur Kluge, Krishna Murthi, Kollol Pal
  • Assays and reagents for identifying anti-fungal agents, and uses related thereto
    Patent number: 6277564
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis. Another aspect of the present invention relates to novel Candida genes and gene products.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: August 21, 2001
    Assignee: GPC Biotech Inc.
    Inventors: Vivian Berlin, Veronique Damagnez, Susan E. Smith
  • Assays and reagents for identifying anti-fungal agents, and uses related thereto
    Patent number: 6271197
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis. Another aspect of the present invention relates to novel Candida genes and gene products.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: August 7, 2001
    Assignees: GPC-Biotech Inc., The Johns Hopkins University
    Inventors: Vivian Berlin, David E. Levin, Yoshikazu Ohya, Veronique Damagnez, Susan E. Smith
  • Immunosuppressant target proteins
    Patent number: 6150137
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: November 21, 2000
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Vivian Berlin, Maria Isabel Chiu, Guillaume Cottarel, Veronique Damagnez
  • Immunosuppressant target proteins
    Patent number: 6127521
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: October 3, 2000
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Vivian Berlin, Maria Isabel Chiu, Guillaume Cottarel, Veronique Damagnez
  • Assays and reagents for identifying anti-fungal agents and uses related thereto
    Patent number: 6117641
    Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis.
    Type: Grant
    Filed: April 11, 1996
    Date of Patent: September 12, 2000
    Assignees: Mitotix, Inc., The John Hopkins University
    Inventors: Vivian Berlin, David E. Levin, Yoshikazu Ohya
  • Ubiquitin conjugating enzymes
    Patent number: 6068982
    Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as p53, p27, myc, fos, MAT.alpha.2, or cyclins. The invention further relates to novel ubiquitin-conjugating enzymes, and uses related thereto.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: May 30, 2000
    Assignee: Mitotix, Inc.
    Inventors: Mark Rolfe, Maria Isabel Chiu, Guillaume Cottarel, Vivian Berlin, Veronique Damagnez, Giulio Draetta
  • Ubiquitin conjugating enzymes
    Patent number: 5968761
    Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as p53, p27, myc, fos, MAT.alpha.2, or cyclins. The invention further relates to novel ubiquitin-conjugating enzymes, and uses related thereto.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 19, 1999
    Assignee: Mitotix, Inc.
    Inventors: Mark Rolfe, Maria Isabel Chiu, Guillaume Cottarel, Vivian Berlin, Veronique Damagnez, Giulio Draetta